Related Experiment Videos

TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery

Jun-Won Yun1, Jung A Seo, Yeon Su Jeong

  • 1Pharmaceutical Research Institute, Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, Yongin 446-729, Republic of Korea.

Journal of Dermatological Science
|February 25, 2011
PubMed
Abstract

Insights

Blocking the Transient Receptor Potential Vanilloid type 1 (TRPV1) channel with PAC-14028 accelerates skin barrier recovery. This TRPV1 antagonism effectively alleviates atopic dermatitis symptoms by improving skin barrier function.

Area of Science:

  • Dermatology
  • Pharmacology
  • Molecular Biology

Background:

  • Transient Receptor Potential Vanilloid type 1 (TRPV1) channels are activated by noxious stimuli and implicated in skin barrier function.
  • Dysfunctional skin barrier is a hallmark of various skin disorders, including atopic dermatitis (AD).

Purpose of the Study:

  • To investigate the efficacy of a novel TRPV1 antagonist, PAC-14028, in accelerating skin barrier repair.
  • To evaluate the potential of PAC-14028 in alleviating atopic dermatitis (AD)-like symptoms.

Main Methods:

  • TRPV1 antagonistic activity of PAC-14028 was assessed via capsaicin-evoked calcium influx in keratinocytes and blood perfusion.
  • Skin barrier recovery was studied in vivo using tape-stripping-induced barrier disruption in hairless mice.
  • AD-like symptoms were evaluated in Dermatophagoides farina (Df) and oxazolone (OXZ) induced mouse models.

Main Results:

  • PAC-14028 demonstrated potent TRPV1 antagonism, inhibiting capsaicin-induced responses and accelerating skin barrier recovery in mice.
  • The compound reduced trans-epidermal water loss (TEWL), normalized lipid layers, and restored key protein expression in AD models.
  • PAC-14028 significantly alleviated AD-like symptoms, including reduced IgE levels, mast cell degranulation, scratching, and clinical dermatitis severity.

Conclusions:

  • Blockade of TRPV1 activation by PAC-14028 accelerates skin barrier repair.
  • TRPV1 antagonism is a promising therapeutic strategy for suppressing atopic dermatitis symptoms by enhancing skin barrier function.

Related Concept Videos

Thermosensation01:43

Thermosensation

Peripheral thermosensation is the perception of external temperature. A change in temperature (on the surface of the skin and other tissues) is detected by a family of temperature-sensitive ion channels called Transient Receptor Potential, or TRP, receptors. These receptors are located on free nerve endings. Those detecting cold temperatures are closer to the surface of the skin than the nerve endings detecting warmth. These thermoTRP channels, while temperature selective, have relatively...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...